CN103585133B - A kind ofly prepare the method that cancerous cell targeting imitates cell microcapsule - Google Patents
A kind ofly prepare the method that cancerous cell targeting imitates cell microcapsule Download PDFInfo
- Publication number
- CN103585133B CN103585133B CN201310566240.3A CN201310566240A CN103585133B CN 103585133 B CN103585133 B CN 103585133B CN 201310566240 A CN201310566240 A CN 201310566240A CN 103585133 B CN103585133 B CN 103585133B
- Authority
- CN
- China
- Prior art keywords
- cell
- microcapsule
- imitative
- aptamer
- cell microcapsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 66
- 230000008685 targeting Effects 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims abstract description 16
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims abstract description 28
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims abstract description 28
- 108091023037 Aptamer Proteins 0.000 claims abstract description 22
- 239000008363 phosphate buffer Substances 0.000 claims abstract description 15
- 230000008569 process Effects 0.000 claims abstract description 7
- 229920000936 Agarose Polymers 0.000 claims abstract description 4
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 4
- 239000000725 suspension Substances 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 claims description 4
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 claims description 4
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 claims description 4
- 239000004531 microgranule Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 2
- 230000012447 hatching Effects 0.000 abstract description 2
- 238000002372 labelling Methods 0.000 abstract description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 230000009881 electrostatic interaction Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 67
- 238000002835 absorbance Methods 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004218 Orcein Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000019248 orcein Nutrition 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses and a kind ofly prepare the method that cancerous cell targeting imitates cell microcapsule.Select heparin-agarose affinity chromatography to wear amino imitative cell microcapsule as raw material preparation table, be dispersed in the aptamer solution containing aldehyde radical; After hatching a period of time, aptamer labelling, to imitative cell microcapsule surface, then washs with phosphate buffer; Imitative cell microcapsule after process is immersed in the drug solution of doxorubicin hydrochloride, by electrostatic interaction drug loading, finally obtains the imitative cell microcapsule of different drug loading.Preparation method of the present invention is easy to be controlled, and material source is extensive, and production efficiency is high, can regulate the drug loading of imitative cell microcapsule easily, have the feature of target cancer cell simultaneously, have good application prospect.
Description
Technical field
The present invention relates to and a kind ofly prepare the method that cancerous cell targeting imitates cell microcapsule.Especially aptamer modified imitative cell microcapsule is utilized to realize the method for cancerous cell targeting.
Background technology
The targeting of pharmaceutical carrier is a very important concept.Pharmaceutical carrier can improve the concentration of medicine at tumor tissues to the specific recognition of cancerous cell, therefore significantly can reduce dosage, thus reduces the toxic and side effects of normal tissue or cell.Therefore, the targeting realizing pharmaceutical carrier has very important significance in drug delivery field.
The common pharmaceutical carrier with target function mainly uses the polymer of synthetic or the protein of natural origin and polysaccharide as raw material, and it is relatively simple for structure.But often poor biocompatibility, is more easily removed by the immune system recognition of human body, have targeting cancerous tissue and the not strong shortcoming of cell ability, these shortcomings limit its propagation and employment.
Imitative cell microcapsule space in capsule and the capsule external space is kept apart by cell membrane the spherical material formed.Utilize cytochalasin b process mammalian cell, destroy the assembling of the actin maintaining cellular morphology, then the imitative cell microcapsule of preparation under the effect of mechanical shearing.
Imitative cell microcapsule has plurality of advantages as the pharmaceutical carrier of cancerous cell targeting: be that small-molecule drug can be embedded on microcapsule inside or cyst wall by the effect such as hydrogen bond, hydrophobic interaction because microcapsule surface essence is one deck class membrane structure on the one hand; Therefore effectively can avoid the generation of medicine violent release phenomenon, also can reduce the murder by poisoning of drug molecule to cell simultaneously.On the other hand, be different from the micro-nano carrier that traditional chemical is modified, imitative cell microcapsule derives from cell, therefore has splendid biocompatibility, and is expected to the scavenging action reducing autoimmune system, has better clinical value.
Aptamer AS1411 is the oligonucleotide being rich in G, and it can be combined with the paranuclein of cancer cell surfaces specifically, thus realizes target function.Experiment before proves that it can be enriched to cancerous tissue and cell, and the propagation of anticancer.
Summary of the invention
The object of this invention is to provide and a kind ofly easyly prepare the method that cancerous cell targeting imitates cell microcapsule fast.
The method preparing the imitative cell microcapsule of cancerous cell targeting of the present invention, comprises the following steps:
1) have in the culture plate of heparin-agarose affinity chromatography and add in cultivation the cytochalasin b solution that 20 μ L concentration are 1mg/mL, at 37 DEG C, hatch 30min; Phosphate buffer is washed for several times, collected by trypsinisation cell, vortex process gained cell, and centrifuging and taking supernatant, obtains imitative cell microcapsule suspension;
2) the imitative cell microcapsule suspension getting 1mg step 1) gained joins end modifiedly to be had in the aptamer solution of aldehyde radical, makes the concentration of aptamer be 1 μ g/mL; 4h is hatched at 37 DEG C; Collected by centrifugation gained microgranule, washing, obtains aptamer modified imitative cell microcapsule;
3) 200 μ g steps 2 are got) the imitative cell microcapsule of gained joins in doxorubicin hydrochloride solution, makes the concentration of doxorubicin hydrochloride be 40 ~ 200 μ g/mL, hatch 3 ~ 24h for 37 DEG C; Collected by centrifugation gained microgranule, washing, the cancerous cell targeting obtaining loading doxorubicin hydrochloride imitates cell microcapsule.
In the present invention, said aptamer is AS1411, its sequence: 5 '-GGTGGTGGTGGTTGTGGTGGT-GGTGG.
Principle of the present invention: add aptamer AS1411 solution in imitative cell microcapsule, by aptamers with aldehyde radical and the amino of imitative cell microcapsule surface protein react AS1411 be grafted to imitative cell microcapsule surface.Again it is mixed with doxorubicin hydrochloride solution, carry out drug loading.Aptamer and doxorubicin hydrochloride give imitative cell microcapsule respectively with targeting and the function of killing and wounding cancerous cell.
Beneficial effect of the present invention is:
Present invention process process is simple, and preparation speed is fast, and controllability is good, and material source, in n cell, has superior biocompatibility and transmits performance; Aptamer molecule and imitative cell microcapsule with active reactive group is utilized to carry out reaction in-situ, conservation and density by controlling the surperficial aptamers of rate of charge regulation and control microcapsule; The imitative cell microcapsule obtained, owing to having aptamer and doxorubicin hydrochloride simultaneously, is provided with better targeting and the character of killing and wounding cancerous cell.
Accompanying drawing explanation
Fig. 1 is the fluorescence photo of the imitative cell microcapsule being marked with cell membrane red fluorescence probe DiI, and microcapsule is dispersed in phosphate buffer.
Fig. 2 is the fluorescence photo of the aptamer modified imitative cell microcapsule being grafted with orchil Cy3 labelling, and microcapsule is dispersed in phosphate buffer.
Fig. 3 is the fluorescence photo after cancerous cell targeting microcapsule load doxorubicin hydrochloride, and microcapsule is scattered in phosphate buffer.
Fig. 4 is the drug loading of cancerous cell targeting microcapsule and the relation of drug level of the load doxorubicin hydrochloride of embodiment 1-3 gained.
Fig. 5 is the drug loading of cancerous cell targeting microcapsule and the relation of incubation time of the load doxorubicin hydrochloride of embodiment 4-6 gained.
Detailed description of the invention
Further illustrate the present invention below in conjunction with example, but these examples are not used for limiting the present invention.
Embodiment 1
1) have in the culture plate of heparin-agarose affinity chromatography add 20 μ L cytochalasin b solution (concentration is 1mg/mL) in cultivation, after hatching 30min at 37 DEG C, wash three times, trypsinization, centrifugal collecting cell with phosphate buffer; Vortex process gained cell 1min; Collected by centrifugation gained supernatant is imitative cell microcapsule suspension.
The imitative cell microcapsule of the above-mentioned gained of 200 μ g is dispersed in 1mL phosphate buffer; Add the cell membrane orchil DiI of 10 μ L1mg/mL wherein, make its mix homogeneously, hatch 15min; Gained is imitated cell microcapsule centrifuge washing for several times with remove unmarked on dyestuff; The fluorescence photo being dispersed in the imitative cell microcapsule in phosphate buffer is shown in Fig. 1.
2) the imitative cell microcapsule suspension getting 1mg step 1) gained joins end modifiedly to be had in the aptamer solution of aldehyde radical, and make the concentration of aptamer be 1 μ g/mL, hatch 4h at 37 DEG C, centrifugal, phosphate buffer is washed for several times; The fluorescence photo obtaining aptamer modified imitative cell microcapsule is shown in Fig. 2.
3) 200 μ g steps 2 are got) the imitative cell microcapsule of gained joins in doxorubicin hydrochloride solution, makes the concentration of doxorubicin hydrochloride be 40 μ g/mL, hatch 12h for 37 DEG C; Centrifugal phosphate buffer washes three times.Obtain loading the fluorescence photo that the cancerous cell targeting of doxorubicin hydrochloride imitates cell microcapsule and see Fig. 3.The drug loading obtaining this microcapsule according to the absorbance at 543nm place in ultraviolet spectrogram is 1.5 μ g, sees Fig. 4.
Embodiment 2
With embodiment 1, difference is step 3), gets 200 μ g steps 2) the imitative cell microcapsule of gained joins in doxorubicin hydrochloride solution, makes the concentration of doxorubicin hydrochloride be 80 μ g/mL, hatch 12h for 37 DEG C; Centrifugal phosphate buffer washes three times.The cancerous cell targeting obtaining loading doxorubicin hydrochloride imitates cell microcapsule.The drug loading obtaining this microcapsule according to the absorbance at 543nm place in ultraviolet spectrogram is 2.1 μ g, sees Fig. 4.
Embodiment 3
With embodiment 1, difference is step 3), gets 200 μ g steps 2) the imitative cell microcapsule of gained joins in doxorubicin hydrochloride solution, makes the concentration of doxorubicin hydrochloride be 200 μ g/mL, hatch 12h for 37 DEG C; Centrifugal phosphate buffer washes three times.The cancerous cell targeting obtaining loading doxorubicin hydrochloride imitates cell microcapsule.The drug loading obtaining this microcapsule according to the absorbance at 543nm place in ultraviolet spectrogram is 6.5 μ g, sees Fig. 4.
Embodiment 4
With embodiment 1, difference is step 3), gets 200 μ g steps 2) the imitative cell microcapsule of gained joins in doxorubicin hydrochloride solution, makes the concentration of doxorubicin hydrochloride be 200 μ g/mL, hatch 3h for 37 DEG C; Centrifugal phosphate buffer washes three times.The cancerous cell targeting obtaining loading doxorubicin hydrochloride imitates cell microcapsule.The drug loading obtaining this microcapsule according to the absorbance at 543nm place in ultraviolet spectrogram is 2.1 μ g, sees Fig. 5.
Embodiment 5
With embodiment 1, difference is step 3), gets 200 μ g steps 2) the imitative cell microcapsule of gained joins in doxorubicin hydrochloride solution, makes the concentration of doxorubicin hydrochloride be 200 μ g/mL, hatch 24h for 37 DEG C; Centrifugal phosphate buffer washes three times.The cancerous cell targeting obtaining loading doxorubicin hydrochloride imitates cell microcapsule.The drug loading obtaining this microcapsule according to the absorbance at 543nm place in ultraviolet spectrogram is 7.0 μ g, sees Fig. 5.
Claims (2)
1. prepare the method that cancerous cell targeting imitates cell microcapsule, comprise the following steps:
1) have in the culture plate of heparin-agarose affinity chromatography and add in cultivation the cytochalasin b solution that 20 μ L concentration are 1mg/mL, at 37 DEG C, hatch 30min; Phosphate buffer is washed for several times, collected by trypsinisation cell, vortex process gained cell, and centrifuging and taking supernatant, obtains imitative cell microcapsule suspension;
2) the imitative cell microcapsule suspension getting 1mg step 1) gained joins end modifiedly to be had in the aptamer AS1411 solution of aldehyde radical, makes the concentration of aptamer be 1 μ g/mL; 4h is hatched at 37 DEG C; Collected by centrifugation gained microgranule, washing, obtains the imitative cell microcapsule that aptamer AS1411 modifies;
3) 200 μ g steps 2 are got) the imitative cell microcapsule of gained joins in doxorubicin hydrochloride solution, makes the concentration of doxorubicin hydrochloride be 40 ~ 200 μ g/mL, hatch 3 ~ 24h for 37 DEG C; Collected by centrifugation gained microgranule, washing, the cancerous cell targeting obtaining loading doxorubicin hydrochloride imitates cell microcapsule.
2. according to claim 1ly prepare the method that cancerous cell targeting imitates cell microcapsule, it is characterized in that said aptamer is AS1411, its sequence: 5 '-GGTGGTGGTGGTTGTGGTGGT-GGTGG.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310566240.3A CN103585133B (en) | 2013-11-13 | 2013-11-13 | A kind ofly prepare the method that cancerous cell targeting imitates cell microcapsule |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310566240.3A CN103585133B (en) | 2013-11-13 | 2013-11-13 | A kind ofly prepare the method that cancerous cell targeting imitates cell microcapsule |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103585133A CN103585133A (en) | 2014-02-19 |
CN103585133B true CN103585133B (en) | 2015-08-12 |
Family
ID=50075588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310566240.3A Active CN103585133B (en) | 2013-11-13 | 2013-11-13 | A kind ofly prepare the method that cancerous cell targeting imitates cell microcapsule |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103585133B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103920161A (en) * | 2014-03-27 | 2014-07-16 | 浙江大学 | Method for efficiently loading medicines in cell membrane microcapsules |
CN105311632A (en) * | 2015-10-27 | 2016-02-10 | 浙江大学 | Preparation method of cell membrane vesicles loading photodynamic therapy drugs |
-
2013
- 2013-11-13 CN CN201310566240.3A patent/CN103585133B/en active Active
Non-Patent Citations (3)
Title |
---|
Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer;W.Xu,et al;《Biomaterials》;20130411;第34卷;第5244-5253页 * |
Preparation, characterization, and in vivo evaluation of doxorubicin loaded BSA nanoparticles with folic acid modified dextran surface;H.Hao,et al;《International Journal of Pharmaceutics》;20130128;第444卷;第77-84页 * |
核酸适配体在抗肿瘤药物主动靶向传递中的应用;周文虎等;《中国医药工业杂志》;20121231;第43卷(第6期);第490-495页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103585133A (en) | 2014-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jiang et al. | Engineered extracellular vesicles for bone therapy | |
JP6606085B2 (en) | Method for producing human cells having increased colony generating ability and proliferation ability | |
JP2009514546A (en) | Collagen skin substitute with improved porosity and tensile strength and its culture method using mechanical stimulation system | |
CN108143718B (en) | Anti-tumor nano gene medicine and preparation method and application thereof | |
KR20140020290A (en) | Methods for treating radiation or chemical injury | |
CN102895665B (en) | Preparation method of targeting graphene nano-grade drug carrier | |
KR102316913B1 (en) | Artificial tissue model comprising hydrogel structure with microchannel network | |
US20120276066A1 (en) | Peptide Linked Cell Matrix Materials for Stem Cells and Methods of Using the Same | |
CN109735496A (en) | A kind of tumour cell chemotherapeutics three-dimensional resistant models and its method for building up | |
Nicholas et al. | Exploiting a Rose Bengal-bearing, oxygen-producing nanoparticle for SDT and associated immune-mediated therapeutic effects in the treatment of pancreatic cancer | |
Munteanu et al. | Adipocyte-based cell therapy in oncology: the role of cancer-associated adipocytes and their reinterpretation as delivery platforms | |
CN105734006B (en) | Preparation method of acellular sodium alginate bionic hydrogel | |
CN105288622A (en) | Preparation method of cell membrane microcapsule simultaneously loaded with chemotherapeutic drug and photodynamic therapeutic drug | |
CN103585133B (en) | A kind ofly prepare the method that cancerous cell targeting imitates cell microcapsule | |
Su et al. | Membrane-binding adhesive particulates enhance the viability and paracrine function of mesenchymal cells for cell-based therapy | |
CN114149965A (en) | Preparation method of ultrapure fresh and live exosome | |
CN102441363A (en) | Adsorbent used for clearing cancer cells in blood | |
Zhou et al. | Ovalbumin-modified nanoparticles increase the tumor accumulation by a tumor microenvironment-mediated “giant” | |
ES2778029T3 (en) | Magnetic extracellular matrix | |
CN113262212A (en) | Cell membrane microvesicle targeting inflammatory region and application thereof | |
CN103920161A (en) | Method for efficiently loading medicines in cell membrane microcapsules | |
Ghosh et al. | Muscle cell proliferation using water-soluble extract from nitrogen-fixing cyanobacteria Anabaena sp. PCC 7120 for sustainable cultured meat production | |
CN102146416B (en) | Cationized pleurotus eryngii polysaccharide nanoparticle genetic transmission system and preparation method thereof | |
CN103627745A (en) | Embedding-crosslinking method for preparing nicotinic acid by Gibberella immobilization bioconversion | |
CN104152520A (en) | Preparation method of walnut polypeptide-zinc chelate with antitumor activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |